Evonik and Ethris partner to expand offerings for nucleic acid delivery

Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support

Navin Fluorine inaugurates Phase-1 of new cGMP-4 facility of Navin Molecular at Devas

The cGMP-4 facility will further strengthen the company's ability to serve global partners

HealthEdge and UST HealthProof Merge to create AI-powered healthcare payer technology

Combination creates a leading, next generation claims operating system for payers, with end-to-end AI capabilities for claims, payments, care & utilization management, payment integrity, and member engagement, serving 115+ health plans

FDA approves sBLA for Takeda's Vonvendi for Von Willebrand disease

Vonvendi is the only recombinant Von Willebrand factor replacement therapy with approved indications in adults and children with VWD

Aptar Pharma partners with Dianosic to advance ARIS platform for treatment of chronic allergic rhinitis and rhinosinusitis

Agreement further expands Aptar Pharma’s leading position in nasal delivery solutions and addresses significant unmet needs of delivering drugs locally over extended periods

Glenmark initiates multi-country Phase 3 clinical trial for Envafolimab in resectable Stage III NSCLC

The company has received approval from DCGI to begin patient enrolment and dosing in the country

Poly Medicure to acquire 90% stake in PendraCare Group for € 18.3 million

PendraCare Group develops, manufactures and sells innovative cardiology catheter solutions and provides design, development and manufacturing services to other global OEM’s

Indegene opens new center in Pune

Granules India and NIPER S.A.S Nagar launch CoE for sustainable pharma innovation

It will focus on interface between API and formulation manufacturing, reducing carbon footprint in formulation production, creating intellectual property, training next-generation scientists, and setting new industry benchmarks

CapVest to acquire majority stake in STADA

Bain Capital and Cinven will each retain a minority stake, reflecting their ongoing confidence in STADA’s future growth